Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...

On Saturday, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) said adolescent patients with severe alopecia areata (AA) treated with once-daily oral baricitinib 4 mg and 2 mg saw ...

Circular Genomics, a biotechnology company, announced Monday that it had moved its headquarters from Albuquerque to San Diego, California. The company specializes in neurology and psychiatry research, ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.